SCHEMBL502439

SCHEMBL502439

CC/C(=C\c1ccc(Br)cc1)C(=O)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
LMNA P02545 4/20 0.49
MEN1 O00255 3/20 0.49
MAPT P10636 3/20 0.49
MAPK1 P28482 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
S1PR4 O95977 1/20 0.49
S1PR1 P21453 1/20 0.49
AKR1C3 P42330 2/20 0.43
TBXAS1 P24557 2/20 0.43
PTGS2 P35354 1/20 0.41
ALDH1A1 P00352 3/20 0.39
RECQL P46063 3/20 0.39
USP2 O75604 2/20 0.39
POLB P06746 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TLR9 Q9NR96 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GPR183 P32249 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL502440 1.00 KMT2A (0.49) KMT2ALMNAMEN1MAPTMAPK1
SCHEMBL5613678 0.89 LMNA (0.51) KMT2ALMNAMEN1MAPTMAPK1
SCHEMBL4218085 0.89 LMNA (0.51) KMT2ALMNAMEN1MAPTMAPK1
SCHEMBL15955485 0.84 CYP3A4 (0.55) KMT2ALMNAMEN1AKR1C3TBXAS1
SCHEMBL15955486 0.84 CYP3A4 (0.55) KMT2ALMNAMEN1AKR1C3TBXAS1
SCHEMBL4606486 0.83 GRIK1 (0.53) KMT2AMEN1MAPTAKR1C3TBXAS1
SCHEMBL4606493 0.83 GRIK1 (0.53) KMT2AMEN1MAPTAKR1C3TBXAS1
SCHEMBL11319459 0.79 LMNA (0.49) KMT2ALMNAMEN1MAPTMAPK1
SCHEMBL11319464 0.79 LMNA (0.49) KMT2ALMNAMEN1MAPTMAPK1
SCHEMBL5173409 0.79 TBXAS1 (0.58) KMT2AMEN1AKR1C3TBXAS1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106085-B2 Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-01-31 US disclosed
US-7994200-B2 Central nervous system disorders; respiratory system disorders; sexual or reproductive disorders; eating disorders; antidiabetic agents; cardiovascular disorders; anticancer agents LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2011-08-09 US disclosed
US-20090131497-A1 INDOLINE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-05-21 US disclosed
US-20090054509-A1 Octahydropentalene-Substituted Pyrazoline Derivatives, Their Prepartion and Use as Medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-02-26 US disclosed
US-20080293797-A1 Cycloalkane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-11-27 US disclosed
US-20080269201-A1 Azepane- or Azocane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-10-30 US disclosed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1937668-A1 OCTAHYDROPENTALENE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS Laboratorios del Dr. Esteve S.A. (ES) 2008-07-02 EP disclosed
EP-1917247-A1 4,5-DIHYDR0-1H-PYRAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS Laboratorios del Dr. Esteve S.A. (ES) 2008-05-07 EP disclosed
US-20070073056-A1 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-29 US disclosed
US-20070073056-A1 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-29 US disclosed
US-20070073056-A1 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-29 US disclosed
WO-2007009722-A1 OCTAHYDROPENTALENE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-25 WO disclosed
WO-2007009689-A1 4,5-DIHYDR0-1H-PYRAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR.ESTEVE, S.A. (ES) 2007-01-25 WO disclosed
WO-2007009689-A1 4,5-DIHYDR0-1H-PYRAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR.ESTEVE, S.A. (ES) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293797-A1 Cycloalkane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments PIGO, BDKRB2, FPR1 KMT2A 4564/4885LMNA 2844/4885MEN1 2392/4885
US-20070073056-A1 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments P2RX4, PIR, P2RY4 KMT2A 2939/4885LMNA 1709/4885MEN1 1294/4885
US-20080269201-A1 Azepane- or Azocane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments AZI2, CYP3A43, ALPI KMT2A 3816/4885LMNA 2413/4885MEN1 236/4885
US-20090054509-A1 Octahydropentalene-Substituted Pyrazoline Derivatives, Their Prepartion and Use as Medicaments CYP11B2, OTC, OAT KMT2A 4463/4885LMNA 1026/4885MEN1 1509/4885
US-20090131497-A1 INDOLINE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS IDO1, PIR, INMT KMT2A 3078/4885LMNA 1935/4885MEN1 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.